Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants
These statements have not been evaluated by the FDA and are not intended to diagnose, treat, or cure. Always check with your physician or veterinarian before starting any new plant based or herbal program including those that utilize hemp.
https://pubmed.ncbi.nlm.nih.gov/35007072/
Richard B van Breemen 1, Ruth N Muchiri 1, Timothy A Bates 2, Jules B Weinstein 2, Hans C Leier 2, Scotland Farley 2, Fikadu G Tafesse 2
Affiliations expand
PMID: 35007072
PMCID: PMC8768006
Free PMC article
Abstract
As a complement to vaccines, small-molecule therapeutic agents are needed to treat or prevent infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants, which cause COVID-19. Affinity selection-mass spectrometry was used for the discovery of botanical ligands to the SARS-CoV-2 spike protein. Cannabinoid acids from hemp (Cannabis sativa) were found to be allosteric as well as orthosteric ligands with micromolar affinity for the spike protein. In follow-up virus neutralization assays, cannabigerolic acid and cannabidiolic acid prevented infection of human epithelial cells by a pseudovirus expressing the SARS-CoV-2 spike protein and prevented entry of live SARS-CoV-2 into cells. Importantly, cannabigerolic acid and cannabidiolic acid were equally effective against the SARS-CoV-2 alpha variant B.1.1.7 and the beta variant B.1.351. Orally bioavailable and with a long history of safe human use, these cannabinoids, isolated or in hemp extracts, have the potential to prevent as well as treat infection by SARS-CoV-2.